Population pharmacokinetics and pharmacodynamics of bolus injection of etomidate in Chinese surgical patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OO-13003851

Enrollment

Unknown

Registered

2013-08-24

Start date

2012-07-26

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anesthesia

Interventions

etomidate:etomidate 0.3mg/kg

Eligibility

Sex/Gender

All

Age

23 Years to 75 Years

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists status I or II adults undergoing elective surgery, written informed consent

Exclusion criteria

Exclusion criteria: Allergic to etomidate or lipid emulsion, neurologic disease or abnormal EEG, treated with any sedative, hypnotic, antipsychotic or antiepileptic drugs, severe cardiac or pulmanory disease, insufficient adrenal gland, diabetes mellitus, hyperkalemia, or pregnancy.

Design outcomes

Primary

Measure	Time frame
plasma concentration of drug;BIS;	—

Countries

China

Contacts

Public ContactXu Chuanya

Peking University Third Hospital

chuanya_xu@163.com+86 13439975517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026